US bill approval protects biomaterials suppliers
This article was originally published in Clinica
The US Senate Commerce Committee approved a tort reform bill on May 1st that among other things would protect biomaterial suppliers from lawsuits alleging harm from an implantable medical device. The bill, sent to the Senate floor on a party-line 11-9 vote, is similar to the measure passed by Congress last year that would limit damage awards in lawsuits over faulty products. That bill was vetoed by President Clinton although he said at the time he supported the biomaterials provision.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.